Repligen (NASDAQ:RGEN) Posts Earnings Results, Beats Estimates By $0.09 EPS

Repligen (NASDAQ:RGEN) posted its quarterly earnings results on Tuesday. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09, Briefing.com reports. The company had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The firm’s revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.23 EPS. Repligen updated its FY24 guidance to $1.50-1.58 EPS and its FY 2024 guidance to 1.500-1.580 EPS.

Repligen Stock Down 5.3 %

NASDAQ:RGEN traded down $8.04 during mid-day trading on Thursday, hitting $142.43. 748,275 shares of the company’s stock traded hands, compared to its average volume of 660,235. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The company has a market capitalization of $7.98 billion, a P/E ratio of -389.94, a P/E/G ratio of 4.27 and a beta of 0.96. The company has a fifty day moving average of $141.59 and a 200 day moving average of $144.78. Repligen has a twelve month low of $113.50 and a twelve month high of $211.13.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Benchmark reissued a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Stephens restated an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a report on Tuesday, July 30th. Wells Fargo & Company assumed coverage on shares of Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price on the stock. Finally, StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Wednesday. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Insider Transactions at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This trade represents a 13.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.